CD14 and metastatic melanoma: Since the frequency of CD14+CD16−MHCIIhigh monocytes before PD1 ICB treatment was a strong predictor of progression-free and overall survival in patients with metastatic melanoma,50 the study of monocytes and their differentiation capacity in tumors remain of critical importance.